Akero Looks To Accelerate Path To Pivotal NASH Data With Phase IIb/III Protocol

89Bio Builds Case For Safety Advantage As FGF Competition Heats Up

 
• By Joseph Haas
adaptive design - text in vintage letterpress wood type against grunge metal surface
Akero's Phase IIb/III adaptive trial is a first in NASH

More from Clinical Trials

More from R&D